THE PAUL LAXALT GROUP for THE ROGOSIN INSTITUTE
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report | Jan 25, 2019 | $30,000 | Replaced |
| 4th Quarter - Termination (this page) | Apr 22, 2019 | $30,000 | Yes |
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Legislation and regulations relating to Medicare policies that impact care provided to patients with kidney disease.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TOM LORANGER | — |
Medical/Disease Research/Clinical Labs MED
Monitor issues concerning improvements in medical research and treatment of kidney disease. Dialysis PATIENTS Demonstration Act of 2017 - HR 4143 and S 2065 The Chronic Kidney Disease Improvement in Research and Treatment Act of 2017 - HR 2644 and S 1980
| Lobbyist | Covered position, as disclosed |
|---|---|
| TOM LORANGER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.